X0609 4 2026-05-18 0001781174 Acrivon Therapeutics, Inc. ACRV 0001950499 Blume-Jensen Peter false C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 true true false false President and CEO 0001950501 Masson Kristina false C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 true true false false EVP - Business Operations false Common Stock 2026-05-18 4 A false 180095 0 A 2259046 D Common Stock 2026-05-18 4 A false 72706 0 A 386343 I See Footnote These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. /s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen 2026-05-20 /s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson 2026-05-20